drugset
drugset / Trial / NCT06709131

A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia

NCT06709131 ↗

Phase 1 Suspended 24 enrolled He Huang
NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Timeline

Start
2025-01-08
Primary completion
2025-08-17
Completion
2026-08-17

Outcome

Outcome not reported

Stopped: “Product manufacturing process improvement”

Drugs

EvaluationDrugModalityDoseRoute
Subject CT0991 Unknown — —

Indications

acute myeloid leukemia